Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation
Not intended for U.S. and UK Media – Radiological Society of North America (RSNA) 2023 Annual Meeting
First presentation of Phase II data for the development compound gadoquatrane, Bayer’s investigational MRI contrast agent, at RSNA 2023 / Publication of a novel health economic model, analyzing cost effectiveness and capacity needs of supplemental screening modalities for dense breasts / Comprehensive program focused on innovation in AI – hosted jointly by teams from Calantic™ Digital Solutions and Blackford Analysis / Bayer’s Experience Center offers immersive tour through radiology clinic of the future
Abstract: No. 3922 Session No. W7-SSNR13
Berlin, November 22, 2023 – Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI). The company announced that new clinical data for gadoquatrane, Bayer’s investigational macrocyclic gadolinium-based compound currently in Phase III development, will be presented at the 2023 Radiological Society of North America (RSNA) Annual Meeting – taking place from November 26 to 30, 2023, in Chicago, USA. Bayer also announced the results of a recently published paper on the cost effectiveness of supplemental screening methods for women with dense breasts in the U.S., to provide greater certainty around the clinical and economic benefits of supplemental screening methods. In addition, Bayer announced four collaboration agreements with the aim to further expand the offering on its medical imaging platform Calantic™ Digital Solutions.
The activities at RSNA reflect Bayer’s commitment as a leading company in key areas of radiology to address today’s industry challenges and accelerate innovation for the benefit of patients and their clinicians, including harnessing the vast potential of artificial intelligence (AI).
New clinical data for investigational contrast agent gadoquatrane being presented at RSNA 2023
International Multicenter Phase 2 Dose Finding Study of Gadoquatrane: A Dose of 0.04 mmol Gd/ kg body weight (bw) of Gadoquatrane Has Similar Efficacy to 0.1 mmol Gd/kg bw of Gadobutrol
Abstract No. 3922, Session No. W7-SSNR13
- Background: Gadoquatrane, Bayer’s investigational macrocyclic gadolinium-based compound currently in Phase III, has the potential to enable a substantially lower gadolinium dose.
- The Purpose of this Phase II study was to establish a dose of gadoquatrane with similar efficacy as gadobutrol for use in CE-MRI, which is the standard of care in diagnostic imaging procedures of the Central Nervous System (CNS), in adult patients with known or highly suspected CNS lesions.
- The Phase II results supported the further development of gadoquatrane with a dose of 0.04 mmol Gd/kg body weight in a broad Phase III program.
New insights into cost effectiveness and capacity needs of supplemental screening modalities for dense breasts
During RSNA 2023 Bayer will announce the publication of a novel health economic model in the Journal of Medical Economics, funded by Bayer, analyzing cost effectiveness and infrastructural capacity of supplemental imaging modalities for women with dense breasts at average and intermediate risk of breast cancer. While ultrasound had the lowest incremental cost-effectiveness ratios, magnetic resonance imaging (MRI) and contrast-enhanced mammography (CEM) demonstrated the best clinical outcomes, compared to x-ray mammography or digital breast tomosynthesis (DBT) alone. Existing MRI scanner capacity has the potential to meet most of the supplemental screening needs of this population. More information can be found in the link to the publication.
Fostering innovation in Radiology AI
In more than 30 panel discussions, Bayer’s AI team composed jointly of experts from both Calantic™ Digital Solutions and Blackford Analysis as well as external thought leaders, will share insights to help healthcare providers, hospital administrators and developers advance their AI strategy, discussing topics like regulatory challenges in the field of AI in medical imaging, app selection, and how to leverage clinical utility frameworks to assess return on investment (ROI). Partner companies from both Bayer and Blackford will present various app approaches and solutions.
While Blackford provides infrastructure and access to a rich clinical application (ClinApp) ecosystem focused on imaging and analytics, Bayer’s own platform Calantic™ Digital Solutions which is building on technology from Blackford and adding additional workflow and analytics components, delivers access to applications for medical imaging, including those enabled by AI – coming with the value proposition to support diagnosis and increase the throughput of medical imaging examinations. On the occasion of RSNA 2023, Bayer also announced that it will partner with radiology AI technology providers Perspectum Limited, Brainomix Limited, Qure.ai, and Imagine Software – with the aim to further expand the offering on its medical imaging platform CalanticTM Digital Solutions.
In addition, Bayer is offering various tech talks, including pilot “Spark Tank Sessions” where app companies at an early stage can learn new ways to refine their value proposition, and get feedback such as optimal workflow and commercialization pathways from an expert panel. Calantic SPARK, Bayer’s accelerator program for medical imaging app developers to further foster innovation in radiology AI, will showcase its partners Imagine Software (Within Health) and Scanslated. Bayer’s Calantic SPARK is a targeted program to help radiology AI startups of all stages get to market faster by offering advice spanning medical, regulatory, reimbursement expertise, and market access – thereby enabling commercialization and distribution through Calantic™ Digital Solutions.
Blackford, the global strategic AI platform and solutions provider that was acquired by Bayer under the well-established company’s arm’s length model, continues to expand its AI portfolio and global strategic relationships in advance of RSNA. The AI portfolio available via the Blackford Platform now includes over 100 applications from 40 separate partner vendors. Blackford has also recently entered into partnerships with global medical imaging provider Philips, healthcare interoperability provider Rhapsody and enterprise imaging provider Mach7 to support their respective journeys into AI solution provision.
Taking a glimpse at a radiology clinic of the future
Reflecting Bayer’s overall RSNA 2023 theme “Let’s Envision the Future of Radiology”, the Experience Center at Bayer’s main booth (#2519) will offer visitors an immersive tour through a radiology clinic of the future. Here they can discover the company’s digital, integrated, disease-oriented solutions across the entire radiology workflow – through the eyes of a patient. The Experience Center includes 21 different stations along the journey, each with interactive content, including Augmented Reality (AR).
About Radiology at Bayer
As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence – from innovative products to high-quality services – to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by Artificial Intelligence (AI). Bayer’s radiology products generated close to €2bn sales in 2022. Based on the company’s ambition to outperform the radiology market’s average annual growth rate of 5 percent by 2030, Bayer is highly committed to research and development, which includes leveraging AI and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction – from diagnosis to care.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.